Novartis
Novartis blood cancer hope
December 12, 2012Research and Development, Sales and Marketing Jakavi, Novartis, oncology
Two-year data from Novartis’s drug Jakavi suggests that it may improve overall survival in a rare form of cancer versus …
Eylea approval for wet AMD
November 29, 2012Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD
Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …
Pharma manufacturing news in brief
November 20, 2012Manufacturing and Production Alfa Laval, Boehringer, Fujifilm, Health Canada, Novartis
Our latest round-up of manufacturing news includes a facility contract for Alfa Laval, plus updates from Fujifilm, Novartis, Boehringer Ingelheim …
Novartis treatments set for approval
November 19, 2012Sales and Marketing Bexsaro, CHMP, Novartis, exjade
Two Novartis drugs, meningococcal vaccine Bexsero and iron chelation therapy Exjade, have been given positive opinions by the CHMP, with …
Novartis says Canada and Switzerland lift vaccines ban
November 2, 2012Manufacturing and Production Canada, Novartis, Switzerland, vaccines
A temporary suspension on the distribution of flu vaccines made by Novartis has been lifted in Canada and Switzerland. The …
Novartis to build $500 million biotech facility in Singapore
November 1, 2012Manufacturing and Production, Sales and Marketing Jimenez, M&P, Novartis, Singapore
Novartis is overseeing the construction of a biotechnology facility in Singapore that is the result of a $500m investment injection. …
Canada latest country to suspend sales of Novartis vaccines
October 30, 2012Manufacturing and Production Canada, Novartis, vaccines
Canada has said it will suspend sales of two flu vaccines made by Novartis – following in the footsteps of …
EU countries suspend sales of Novartis flu vaccines
October 29, 2012Manufacturing and Production, Sales and Marketing EU, Novartis, vaccines
Contamination of Novartis flu vaccines with white particles has resulted in regulatory actions from various authorities in the EU, including …
Novartis’ MS drug improves outcomes
October 15, 2012Sales and Marketing MS, Novartis, gilenya
Novartis’ multiple sclerosis (MS) drug Gilenya has demonstrated what the manufacturer calls ‘significant’ benefits for patients if used early. Results …
NICE does Lucentis U-turn
October 5, 2012Sales and Marketing Lucentis, NICE, Novartis, Roche, avastin
NICE has done a U-turn over its previous verdict on Novartis’ Lucentis, now recommending the drug in draft guidance to …
Seebri Breezhaler approved in Europe
October 4, 2012Sales and Marketing COPD, Novartis, Relvar, Seebri Breezhaler, Tudorza
Novartis has been given approval in Europe for its Seebri Breezhaler to be used as maintenance treatment for chronic obstructive …
Afinitor’s new UK indication launched
September 20, 2012Sales and Marketing Afinitor, CHMP, Novartis, breast cancer
Novartis’ cancer drug Afinitor has been made available in the UK for patients with the most common form of advanced …
Novartis to file for new Lucentis indication
September 7, 2012Lucentis, Novartis, macular edema, macular oedema, ophthamology
Novartis is set to file eye treatment Lucentis for a new indication. The firm will submit Lucentis (ranibizumab) to the …
Novartis cheered by COPD trial results
September 3, 2012Research and Development COPD, ERS, Novartis
One of Novartis’ experimental respiratory drugs has proved superior in a late-stage trial to Boehringer Ingelheim and Pfizer’s existing brand …
Novartis’ myelofibrosis treatment approved in Europe
August 28, 2012Sales and Marketing Incyte, Jakavi, Novartis, Orphan Drugs, myelofibrosis
Novartis’ Jakavi, a new treatment for patients with myelofibrosis has been approved in Europe. The drug was co-developed with Incyte, …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
